Thailand healthcare market: size, growth and outlook 2026–2032

Southeast Asia's medical-tourism leader with the region's largest listed hospital group. Published estimates normalised to 2025 range from USD 19.3 bn to USD 35.6 bn; the Consulting Wallah central estimate is USD 22.0 bn, growing at about 8% a year to USD 37.7 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by near-universal coverage (99.5% of population) since 2002; government funds ~78% of health spending with OOP only 9.9%; medical tourism: >3 million foreign patients in 2024, 65 JCI-accredited facilities (1st in ASEAN), procedures 50-70% cheaper than Western markets; ageing society - ~13 million aged 60+ (~20% of population) in 2023; ~400,000 NCD deaths a year.

Context that matters for buyers and suppliers: BDMS held 6,486 inpatient beds (~17% of Thai private hospital beds) in 2023 and ~50% of revenue of SET-listed private hospital operators. BDMS operating revenue THB 92.9 bn in 2022 with EBITDA THB 23.9 bn (25.7% margin); international patients ~28% of patient revenue. BDMS network as of 3Q25: 60 hospitals and 9,300+ structured beds (Bangkok Hospital 31 hospitals/4,616 beds; Phyathai 8/1,693; Samitivej 7/1,418). Bumrungrad records >520,000 international patient visits a year; international patients were 66.8% of hospital revenue in 3Q25.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 19.3 bn–USD 35.6 bn; differences are mostly scope.

Included: public and private hospital, clinic, diagnostic and long-term care services and the associated health expenditure. Excluded: pharmaceutical and device product sales, insurance premiums and health IT (covered in separate reports). Published totals differ mainly by whether products and insurance are folded in.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• BDMS held 6,486 inpatient beds (~17% of Thai private hospital beds) in 2023 and ~50% of revenue of SET-listed private hospital operators (TRIS Rating (Oct 2023))
• BDMS operating revenue THB 92.9 bn in 2022 with EBITDA THB 23.9 bn (25.7% margin); international patients ~28% of patient revenue (TRIS Rating)
• BDMS network as of 3Q25: 60 hospitals and 9,300+ structured beds (Bangkok Hospital 31 hospitals/4,616 beds; Phyathai 8/1,693; Samitivej 7/1,418) (BDMS 3Q25 presentation)
• Bumrungrad records >520,000 international patient visits a year; international patients were 66.8% of hospital revenue in 3Q25 (Mordor Intelligence; Kaohoon)
• Government covers 77.8% of health spending; out-of-pocket is 9.9% (2023) (WHO via Feather)
• UCS covers 48 million people with ~THB 265 bn budget; CSMBS spends ~THB 20,000 per head, nearly 4x UCS (KKP via The Star)
• Private hospital revenue in Thailand is about THB 245 bn; only 6.4% of Thais hold voluntary private health insurance (KKP via The Star)
• Over 3 million foreign patients visited Thailand in 2024; private hospitals projected to serve 2.9m inpatients and 26.3m outpatients a year by 2030 (Thailand BOI)
• Thailand has 2.4 hospital beds and 0.54 doctors per 1,000 people (WHO/OECD via Feather)

Where the GCC and India sit

• Thailand health expenditure: 5.54% of GDP; USD 326.5 per capita (2023) — WHO / World Bank via Feather
• Hospital beds per 1,000: 2.4 (latest) — WHO/OECD via Feather
• Doctors per 1,000: 0.54 (2022) — WHO/OECD via Feather
• Private hospital beds: ~35,494 (2023) rising to ~42,182 (2030 projection) (2023) — BOI (chart, unconfirmed labels)
• Foreign patients: >3 million (2024) — BOI
• JCI-accredited facilities: 65 (4th globally, 1st in ASEAN) (2025-11) — BOI

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: wellness and preventive check-up tourism (8.97%-9.46% CAGR) and BDMS Silver Wellness & Residence project (~THB 23.5 bn, launch 2029); growth in Middle East, Bangladesh and Myanmar patient flows (Bumrungrad 3Q25: Bangladesh +31%, Myanmar +21%, Middle East +10%); private bed expansion from ~35,500 (2023) to ~42,200 (2030).

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Operators and investors: capacity, payer rules and licensing timelines decide returns; design central procurement and insurer contracting into the operating model before opening.
• Suppliers: registration, a local partner and payer-formulary presence are the gates; central tenders reward structured quotations and reliable supply over the lowest price.
• Hospital leaders: payer pressure makes the 25–35% of cost in supplies the margin lever — see the free executive assessment.

1. Thailand Board of Investment, Healthcare and Wellness Industry — boi.go.th
2. Nexdigm, Thailand Healthcare Market Report — nexdigm.com
3. Mordor Intelligence, Thailand Medical and Wellness Tourism Market — mordorintelligence.com
4. The Star (Bangkok Post/KKP), Thailand healthcare reform: State funding nears breaking point — thestar.com.my
5. Feather Insurance (WHO/World Bank data), Health & healthcare in Thailand: Statistics, trends & facts (2026) — feather-insurance.com
6. TRIS Rating, TRIS Rating affirms BDMS at AA, stable outlook — trisrating.com
7. BDMS via MarketScreener, BDMS Investor Presentation 3Q25 & 9M25 — marketscreener.com
8. Kaohoon International, Bumrungrad Hospital Reports 4% Profit Growth in 3Q25 — kaohooninternational.com
9. Asia News Network, Q1 2026 headwinds drag on Thai private hospital revenues, profits (not fetched - rate limited) — asianews.network
10. Thailand Board of Investment (BOI) (2025-12) — USD 18.4 bn (2024) to USD 26.6 bn (2030), CAGR ~5% (private hospital spending ~6.1%); scope: country - Thailand healthcare services market; public hospitals >50% of spending; private hospital revenue projected USD 12.9 bn by 2030 — source
11. Nexdigm (2025-07) — USD 31.5 bn (2024) to USD 110 bn (2034), CAGR 13%; scope: country - Thailand healthcare market (broad definition incl. services, medical/wellness tourism); publisher's CAGR period (2024-2030) and forecast endpoint (2034) are inconsistent — source
12. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
13. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.